2-甲基-4-三氟甲基苯硼酸 | 957034-45-6

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-4-三氟甲基苯硼酸
• 英文名称: (2-methyl-4-(trifluoromethyl)phenyl)boronic acid
• 英文别名: 2-Methyl-4-(trifluoromethyl)phenylboronic acid；[2-methyl-4-(trifluoromethyl)phenyl]boronic acid
• CAS: 957034-45-6
• 化学式: C₈H₈BF₃O₂
• 分子量: 203.957
• InChiKey: USEHFBIGOATLIA-UHFFFAOYSA-N

物化性质

• 沸点：
  271.9±50.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.69
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methyl-4-trifluoromethylphenylboronic acid
Synonyms: 2-Methyl-4-(trifluoromethyl)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyl-4-trifluoromethylphenylboronic acid
CAS number: 957034-45-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8BF3O2
Molecular weight: 204.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-4-三氟甲基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成 ethyl 3-(5-(2-(((2-chloro-2'-methyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)amino)methyl)-5-(trifluoromethyl)phenyl)picolinamido)propanoate
  参考文献：
  名称：

  PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及吡咯烷酰基丙酸衍生物，含有它们的药物组合物以及它们在治疗和/或预防通过拮抗一个或多个胰高血糖素受体而改善的疾病和症状中的用途，包括例如代谢性疾病，如2型糖尿病和肥胖症。

  公开号：

  US20120302610A1
• 作为产物：
  描述：

  硼酸三甲酯 、 1-溴-2-甲基-4-三氟甲基苯 、 水 在 正丁基锂 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以1.2 g的产率得到2-甲基-4-三氟甲基苯硼酸
  参考文献：
  名称：

  半偶联和离子对对联苯自由基阳离子还原电位的联合影响

  摘要：

  使用氧化还原平衡梯法测量 1,2-二氯乙烷 (DCE) 中脉冲辐射解产生的取代联苯的高氧化性和短寿命自由基阳离子的形式还原电位。通过利用 DCE在自由基阳离子附近释放 Cl -的能力，研究了卤化物离子-自由基相互作用对联苯还原电位的影响。在超过 700 mV 的范围内测量电位的哈米特相关性显示在高哈米特西格玛值处饱和。这种效应可以通过联苯自由基阳离子和 Cl 之间的离子对和半配位相互作用来解释，并且似乎可以将还原电位调节高达 400 mV。这一发现为操纵涉及有机氧化还原物质的电子转移能量提供了一种便捷的方法。

  DOI：

  10.1021/acs.jpca.3c03817

文献信息

• BENZOXAZINE DERIVATIVES AS CRAC MODULATORS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130090333A1

  公开（公告）日：2013-04-11

  Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

  公式(I)的化合物： 或其药用可接受的盐，其中R1和R2如本文所述定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道（CRAC）相关疾病的用途。
• 4-AZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158066A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement
  作者：Isaac E. Marx、Thomas A. Dineen、Jessica Able、Christiane Bode、Howard Bregman、Margaret Chu-Moyer、Erin F. DiMauro、Bingfan Du、Robert S. Foti、Robert T. Fremeau、Hua Gao、Hakan Gunaydin、Brian E. Hall、Liyue Huang、Thomas Kornecook、Charles R. Kreiman、Daniel S. La、Joseph Ligutti、Min-Hwa Jasmine Lin、Dong Liu、Jeff S. McDermott、Bryan D. Moyer、Emily A. Peterson、Jonathan T. Roberts、Paul Rose、Jean Wang、Beth D. Youngblood、Violeta Yu、Matthew M. Weiss

  DOI：10.1021/acsmedchemlett.6b00243

  日期：2016.12.8

  genetic evidence has identified the voltage-gated sodium channel NaV1.7 as an attractive target for the treatment of pain. We initially identified naphthalene sulfonamide 3 as a potent and selective inhibitor of NaV1.7. Optimization to reduce biliary clearance by balancing hydrophilicity and hydrophobicity (Log D) while maintaining NaV1.7 potency led to the identification of quinazoline 16 (AM-2099).

  人类遗传证据已将电压门控钠通道Na V 1.7确定为治疗疼痛的引人注目的靶标。我们最初确定萘磺酰胺3是Na V 1.7的有效和选择性抑制剂。通过在保持Na V 1.7效力的同时平衡亲水性和疏水性（Log D）来降低胆汁清除率的优化导致了对喹唑啉16（AM-2099）的鉴定。化合物16在大鼠和狗中显示出良好的药代动力学特征，并在口服给药后在小鼠行为模型中证明了组胺诱导的scratch痒的剂量依赖性降低。
• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2018098499A1

  公开（公告）日：2018-05-31

  The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

  本发明部分涉及融合的杂环化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或症状，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或症状，包括德拉维特综合征或癫痫的方法。
• ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS
  申请人：BOSTRÖM Jonas

  公开号：US20100261755A1

  公开（公告）日：2010-10-14

  or a pharmaceutically suitable salt thereof, wherein, R 1 and R 2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R 3 , R 3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R 3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprising O or N and optionally substituted with a C1-10 alkyl or aryl, hetero aryl optionally substituted with R3.

  或其药学上适用的盐，其中， R1和R2独立地是氢、氘、芳基、杂环芳基、C1-C8烷基，可选地被一个或多个取代基取代，这些取代基独立地是R3， R3是芳基、杂环芳基、氟、含有一个或多个氟的C1-C6烷基、含有一个或多个氘的C1-C6烷基、含有羟基的C1-C6烷基，芳基和杂环芳基可选地被一个或多个卤素、氟代烷氧基、氟代烷基、磺酰基、一个或多个氘、C1-6烷基、C1-6烷氧基、腈取代， 或R3是一个C1-6烷基，可选地被以下一种或多种基团取代：COOR4、OCOR4、CONR5R6、NR5COR6、OR4； 其中，R4是一个C1-10烷基，可选地被一个或多个氟、氘、烷氧基、芳基羧酸酯、烷基羧酸酯取代； R5和R6独立地选自氢、烷基，或它们可以共同形成一个4-8成员碳环； 或R1和R2形成一个3-10成员碳环，可选地包含O或N，并可选地被一个C1-10烷基或芳基、可选地被R3取代。